Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics

British Journal of Psychiatry

Volumn 209, Issue 5, 2016, Pages 361-365

  Murray, Robin M ^a   Quattrone, Diego ^a   Natesan, Sridhar ^a   Van Os, Jim ^b   Nordentoft, Merete ^c   Howes, Oliver ^a   Di Forti, Marta ^a   Taylor, David ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT;

BRAIN SIZE; CLINICAL PRACTICE; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG USE; DYSLIPIDEMIA; HEALTH STATUS; HEART ARRHYTHMIA; HUMAN; INSULIN RESISTANCE; LONG TERM CARE; NONHUMAN; OBESITY; PSYCHIATRIST; PSYCHOSIS; RECEPTOR SENSITIVITY; REVIEW; SCHIZOPHRENIA; SUICIDE; TREATMENT OUTCOME; PSYCHOTIC DISORDERS; SECONDARY PREVENTION; STANDARDS;

ANTIPSYCHOTIC AGENTS; HUMANS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SECONDARY PREVENTION;

EID: 84996564309     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.116182683     Document Type: Review

References (75)

1. Shorter E. A History of Psychiatry: From the Era of the Asylum to the Age of Prozac. John Wiley & Sons, 1997.
2. Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. BMJ 1971; 3: 599-604.
3. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia:a systematic review and meta-analysis. Lancet 2012; 379: 2063-71.
4. Moncrieff J. Antipsychotic maintenance treatment: time to rethink? PLoS Med 2015; 12: e1001861.
5. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 2015; 72: 334-41.
6. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010; 196: 116-21.
7. Hoang U, Stewart R, Goldacre MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. BMJ 2011; 343: d5422.
8. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64: 1123-31.
9. Lawrence D, Kisely S, Pais J. The epidemiology of excess mortality in people with mental illness. Can J Psychiatry 2010; 55: 752-60.
10. Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol 2014; 10: 425-48.
11. Frommeyer G, Eckardt L. Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol 2016; 13: 36-47.
12. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-35.
13. Henderson DC, Vincenzi B, Andrea NV, Ulloa M, Copeland PM. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry 2015; 2: 452-64.
14. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009; 119: 171-9.
15. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012; 8: 114-26.
16. Torniainen M, Mittendorfer-Rutz E, Tanskanen A, Bjorkenstam C, Suvisaari J, Alexanderson K, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 2015; 41: 656-63.
17. Mace S, Dzahini O, Cornelius V, Anthony D, Stewart R, Taylor D. Antipsychotic use and unexpected death: a hospital-based case-control study. Acta Psychiatr Scand 2015; 132: 479-88.
18. Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder? BMJ (Clin Res Ed) 1987; 295: 681-2.
19. van Haren NE, Cahn W, Hulshoff Pol HE, Kahn RS. Schizophrenia as a progressive brain disease. Eur Psychiatry 2008; 23: 245-54.
20. Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol Med 2009; 39: 1763-77.
21. Moncrieff J, Leo J. A systematic review of the effects of antipsychotic drugs on brain volume. Psychol Med 2010; 40: 1409-22.
22. Zipursky RB, Reilly TJ, Murray RM. The myth of schizophrenia as a progressive brain disease. Schizophr Bull 2013; 39: 1363-72.
23. Vita A, De Peri L, Deste G, Sacchetti E. Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Transl Psychiatry 2012; 2: e190.
24. Rais M, Cahn W, van Haren N, Schnack H, Caspers E, Hulshoff Pol H, et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry 2008; 165: 490-6.
25. Karama S, Ducharme S, Corley J, Chouinard-Decorte F, Starr JM, Wardlaw JM, et al. Cigarette smoking and thinning of the brain's cortex. Mol Psychiatry 2015; 20: 778-85.
26. Katon W, Pedersen HS, Ribe AR, Fenger-Gron M, Davydow D, Waldorff FB, et al. Effect of depression and diabetes mellitus on the risk for dementia: a national population-based cohort study. JAMA Psychiatry 2015; 72: 612-9.
27. Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005; 30: 1649-61.
28. Vernon AC, Crum WR, Lerch JP, Chege W, Natesan S, Modo M, et al. Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs - linking magnetic resonance imaging findings to cellular pathology. Biol Psychiatry 2014; 75: 982-90.
29. Konopaske GT, Dorph-Petersen KA, Pierri JN, Wu Q, Sampson AR, Lewis DA. Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology 2007; 32: 1216-23.
30. Vita A, De Peri L, Deste G, Barlati S, Sacchetti E. The effect of antipsychotic treatment on cortical gray matter changes in schizophrenia: does the class matter? A meta-analysis and meta-regression of longitudinal magnetic resonance imaging studies. Biol Psychiatry 2015; 78: 403-12.
31. Boonstra G, van Haren NE, Schnack HG, Cahn W, Burger H, Boersma M, et al. Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia. J Clin Psychopharmacol 2011; 31: 146-53.
32. Vernon AC, Natesan S, Crum WR, Cooper JD, Modo M, Williams SC, et al. Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. Biol Psychiatry 2012; 71: 855-63.
33. Terry AV Jr, Gearhart DA, Warner SE, Zhang G, Bartlett MG, Middlemore ML, et al. Oral haloperidol or risperidone treatment in rats: temporal effects on nerve growth factor receptors, cholinergic neurons, and memory performance. Neuroscience 2007; 146: 1316-32.
34. Terry AV Jr, Hill WD, Parikh V, Evans DR, Waller JL, Mahadik SP. Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. Psychopharmacology 2002; 164: 360-8.
35. Gur RE, Turetsky BI, Bilker WB, Gur RC. Reduced gray matter volume in schizophrenia. Arch Gen Psychiatry 1999; 56: 905-11.
36. Taylor M, Cavanagh J, Hodgson R, Tiihonen J. Examining the effectiveness of antipsychotic medication in first-episode psychosis. J Psychopharmacol 2012; 26: 27-32.
37. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2012; 5: CD008016.
38. Harrow M, Jobe TH, Faull RN. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multifollow- up study. Psychol Med 2014; 44: 3007-16.
39. Moilanen J, Haapea M, Miettunen J, Jaaskelainen E, Veijola J, Isohanni M, et al. Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication - a 10-year follow-up of the Northern Finland 1966 Birth Cohort study. Eur Psychiatry 2013; 28: 53-8.
40. Morgan C, Lappin J, Heslin M, Donoghue K, Lomas B, Reininghaus U, et al. Reappraising the long-term course and outcome of psychotic disorders: the ÆSOP-10 study. Psychol Med 2014; 44: 2713-26.
41. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted firstepisode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007; 68: 654-61.
42. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013; 70: 913-20.
43. McGorry P, Alvarez-Jimenez M, Killackey E. Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more. JAMA Psychiatry 2013; 70: 898-900.
44. Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental cognitive model. Lancet 2014; 383: 1677-87.
45. Smith RC, Davis JM. Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine. Life Sci 1976; 19: 725-31.
46. Grace AA. Dopamine system dysregulation and the pathophysiology of schizophrenia: insights from the methylazoxymethanol acetate model. Biol Psychiatry 2015; doi:10.1016/j.biopsych.2015.11.007.
47. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 2007; 27: 2979-86.
48. Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal 11Craclopride PET study in cats. Neuropsychopharmacology 2009; 34: 662-71.
49. Zakzanis KK, Hansen KT. Dopamine D2 densities and the schizophrenic brain. Schizophr Res 1998; 32: 201-6.
50. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012; 69: 776-86.
51. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology 2000; 152: 174-80.
52. Konig P, Benzer MK, Fritzche H. SPECT technique for visualization of cerebral dopamine D2 receptors. Am J Psychiatry 1991; 148: 1607-8.
53. Mizrahi R, Agid O, Borlido C, Suridjan I, Rusjan P, Houle S, et al. Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophr Res 2011; 131: 63-8.
54. Chouinard G, Jones BD, Annable L. Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 1978; 135: 1409-10.
55. Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, druginduced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 2008; 77: 69-77.
56. Chouinard G, Annable L, Ross-Chouinard A. Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients. Psychopharmacol Bull 1986; 22: 891-6.
57. Tenback DE, van Harten PN, Slooff CJ, van Os J. Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study. Compr Psychiatry 2007; 48: 436-40.
58. Carpenter WT, McGlashan TH, Strauss JS. The treatment of acute schizophrenia without drugs: an investigation of some current assumptions. Am J Psychiatry 1977; 134: 14-20.
59. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 2006; 114: 3-13.
60. Roy-Desruisseaux J, Landry J, Bocti C, Tessier D, Hottin P, Trudel JF. Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia. Ann Pharmacother 2011; 45: e51.
61. Lu ML, Pan JJ, Teng HW, Su KP, Shen WW. Metoclopramide-induced supersensitivity psychosis. Ann Pharmacother 2002; 36: 1387-90.
62. Seeman P. Yes, Breast is best but taper domperidone when stopping (e-letter). Br J Gen Pract 2014; January 15.
63. Joyce JN. D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period. Synapse 2001; 40: 137-44.
64. Quinn R. Comparing rat's to human's age: how old is my rat in people years? Nutrition 2005; 21: 775-7.
65. Corstens D, Longden E, McCarthy-Jones S, Waddingham R, Thomas N. Emerging perspectives from the hearing voices movement: implications for research and practice. Schizophr Bull 2014; 40: S285-94.
66. Corstens D, Longden E, Rydinger B, Bentall R, van Os J. Treatment of hallucinations: a comment. Psychosis 2013; 5: 98-102.
67. Tadokoro S, Okamura N, Sekine Y, Kanahara N, Hashimoto K, Iyo M. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr Bull 2012; 38: 1012-20.
68. Takaesu Y, Kishimoto T, Murakoshi A, Takahashi N, Inoue Y. Factors associated with discontinuation of aripiprazole treatment after switching from other antipsychotics in patients with chronic schizophrenia: a prospective observational study. Psychiatry Res 2016; 236: 71-4.
69. Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry 2014; 75: e11-3.
70. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 2012; 169: 1203-10.
71. Suzuki T, Kanahara N, Yamanaka H, Takase M, Kimura H, Watanabe H, et al. Dopamine supersensitivity psychosis as a pivotal factor in treatmentresistant schizophrenia. Psychiatry Res 2015; 227: 278-82.
72. Oda Y, Kanahara N, Iyo M. Alterations of dopamine D2 receptors and related receptor-interacting proteins in schizophrenia: the pivotal position of dopamine supersensitivity psychosis in treatment-resistant schizophrenia. Int J Mol Sci 2015; 16: 30144-63.
73. Girgis RR, Phillips MR, Li X, Li K, Jiang H, Wu C, et al. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry 2011; 199: 281-8.
74. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 2009; 15: 2550-9.
75. Schizophrenia Commission. The Abandoned Illness. Rethink, 2012.